Table 1.

Patient demographics and characteristics at enrollment

	All patients (N = 102)
Median time from initial HL diagnosis to first dose in months (range)	39.9 (12-220)
Stage at initial diagnosis, n (%)
Stage I/II	51 (50)
Stage III	27 (26)
Stage IV	20 (20)
Unknown	4 (4)
ECOG performance status, n (%)
Grade 0	42 (41)
Grade 1	60 (59)
Patients with primary refractory disease,* n (%)	72 (71)
Disease status relative to most recent prior therapy,† n (%)
Relapse	59 (58)
Refractory	43 (42)
Median number of prior cancer-related systemic therapy regimens‡ (range)	3.5 (1-13)
Median PFS for most recent regimen in months (95% CI)	6.1 (4.4, 7.2)
Number of prior auto-SCTs, n (%)
1	91 (89)
2	11 (11)
Median time from most recent auto-SCT to relapse after auto-SCT in months (range)	6.7 (0-131)

^*Absence of CR or relapse within 3 months of front-line therapy.

^†Relapse indicates the best response of CR or PR to most recent prior therapy, whereas refractory indicates the best response of stable or progressive disease to most recent prior therapy.

^‡Includes chemotherapy given for stem cell mobilization.